You know the one with 4 old rich crusty white men & some lying witch on her communist broom stick. Is that the best the Communist trader party has to offer? My God what a bunch of evil losers...
Northland Capital’s David Buck argues that Mallinckrodt’s (MNK) shares are attractive after dropping more than 15% after being likened to Valeant Pharmaceuticals International (VRX). He explains:
Our thesis on Mallinckrodt shares now trading down ~18% on media reports covering a blogger’s (negative) tweet is that see fundamental value on F2015 (reports 11-23-15) EPS of $7.25 and F2016E EPS of $7.95. Intra-day, Mallinckrodt shares trade at just 7.7x and 7.3x our fiscal year EPS forecasts for 2015/2016. Factoring in net debt of $5.1B ($42.70 per share) Mallinckrodt shares trade at an EBITDA multiple of just under 8x Fiscal 2016 which we see as positive risk-reward. Our fundamental target of $92 per share remains.
Mallinckrodt shares at initiation in mid-October and currently reflect scrutiny of the specialty pharmaceutical group and the company has indicated its F2016 outlook does not rely upon any dramatic pricing growth, particularly for its Acthar (autoimmune) and Ofirmev (acetaminophen) drugs. Mallinckrodt has also previously clarified its lack of ownership of specialty pharmacies, a recent focus of investors.
Deutsche Bank finds value in the airline sector
Deutsche Bank upgrades three airline stocks to a Buy rating from Hold off of attractive valuation on entry points for investors.
American Airlines Group (NASDAQ:AAL) is assigned a price target of $50 to rep 28% upside potential.
Delta Air Lines is also tagged with a $50 PT which works out to 14% upside potential.
Latin America provided Copa Holdings is set with a $65 PT for 27% upside potential
Nomura Securities initiates coverage on Mallinckrodt plc (NYSE: MNK) with a Neutral rating and a price target of $100.00.Analyst Shibani
You fools VRX will earn over $12 this year $15 next year. This peak squeak Philidor accounts for less the 6% of sales. This is a $300 stock on sale because of fear & lies. Once again thanks for the cheap shares.
Mallinckrodt (MNK) Sell-Off Overdone as Competitor Details Lacking - Deutsche Bank (ANIP)
September 21, 2015 11:21 AM EDT Send to a Friend
Deutsche Bank maintained a Buy rating on Mallinckrodt plc (NYSE: MNK) with a price target of $104. Analyst Gregg Gilbert ...
Fiscal 2016 Mallinckrodt Financial Guidance1,2
For fiscal 2016, Mallinckrodt's annual net sales are expected to increase at least 10% on an operational basis, which excludes the impact of fluctuations in foreign currency exchange rates. Net sales for the company's Specialty Brands segment are expected to increase at least 30%. The segment forecast includes net sales for H.P. Acthar® Gel (repository corticotropin injection) and OFIRMEV® (acetaminophen) injection along with full fiscal year net sales contributions from INOMAX® (nitric oxide) for inhalation and the Therakos® immunology platform. Net sales for the company's Specialty Generics segment are expected to decrease 15% to 20%. Net sales for the company's Global Medical Imaging segment (excluding CMDS) are expected to decrease 5% to 10%.
Mallinckrodt expects adjusted diluted earnings per share (EPS) to be in the range of $7.70 to $8.20 for fiscal 2016. Net interest expense is forecasted to be in the range of $370 million to $385 million. The adjusted effective tax rate is expected to be between 15% and 17%. This range reflects an estimated weighted average diluted share count of 118 million to 121 million.
Revenue excluding currency swings will rise at least 10%, Mallinckrodt said. Analysts are looking for $3.65 billion in revenue next year.
American Airlines Group's total revenue passenger miles (RPMs) were 18.1 billion, up 7.2 percent versus September 2014. Total capacity was 21.9 billion available seat miles (ASMs), up 3.7 percent versus September 2014. Total passenger load factor was 82.7 percent, up 2.7 percentage points versus September 2014. The Company's traffic, capacity and load factor were all records for the month of September.
The Company continues to expect its third quarter 2015 consolidated passenger revenue per available seat mile (PRASM) to be down approximately six to eight percent year-over-year. In addition, the Company expects its third quarter pretax margin excluding special items to be between 17 and 18 percent. For more financial forecasting detail, please refer to the Company's investor relations update also filed this morning on SEC Form 8-K.
Are u insane?
Medicare $137 Trillion in debt. Democrat program
Medicaid Plan B $39 Trillion in Debt. Democrat program
SS# $29 Trillion in debt. Democrat program
Obama (a low life democrat) along added $12 trillion to the National debt.
You my friend are a moron Less
AMAG is rated BUY, based on the average of 7 Wall Street analyst ratings. Among these analysts, 71.4% (5) of them have positive ratings on the stock. 0.0% (0) of them have negative ratings. 28.6% (2) of them have neutral ratings. Analysts have an average $66.43 Target Price on AMAG, implying 118.7% Upside to its current price of $30.38.
Revenue miles up 7.5% for Southwest Airlines in August
Southwest Airlines (NYSE:LUV) reports revenue passenger miles increased 7.5% to 10.3B in August.
Capacity was up 7.6% to 12.1B available seat miles.
August load factor -10 bps to 85.4%.
YTD load factor +70 bps to 83.6%.
The company expects operating revenue per available seat mile will decline 1% Y/Y in Q3.
While it beat FQ4 estimates, Micron (NASDAQ:MU) has guided on page 20 of in its earnings slides (.pdf) for FQ1 revenue of $3.35B-$3.6B and EPS of $0.20-$0.26, below a consensus of $3.74B and $0.38